HLA-A01 and HLA-B27 Supertypes, but Not HLA Homozygocity, Correlate with Clinical Outcome among Patients with Non-Small Cell Lung Cancer Treated with Pembrolizumab in Combination with Chemotherapy

彭布罗利珠单抗 医学 内科学 肿瘤科 人类白细胞抗原 肺癌 化疗 人口 癌症 免疫学 免疫疗法 抗原 环境卫生
作者
Afaf Abed,Anna Reid,Ngie Chang Law,Michael Millward,Elin S. Gray
出处
期刊:Cancers [MDPI AG]
卷期号:16 (17): 3102-3102
标识
DOI:10.3390/cancers16173102
摘要

Introduction: Maximal heterozygosity on the human leukocyte antigen (HLA) loci has been found to be associated with improved survival and development of immune-related adverse events (irAEs) among NSCLC patients treated with immunotherapy. Here, we investigated the effect of germline HLA-I/-II on clinical outcomes among NSCLC patients treated with first-line pembrolizumab in combination with chemotherapy. Method: We prospectively recruited patients with NSCLC who were commencing first-line pembrolizumab in combination with chemotherapy. DNA from white blood cells was used for high-resolution HLA-I/II typing. Results: Of the 65 patients recruited, 53 complied with the inclusion criteria. We did not find an association between HLA-I/-II homozygosity and clinical outcome among the studied population. However, the presence of HLA-A01 was associated with unfavourable PFS (HR = 2.32, 95%CI 1.13–4.77, p = 0.022) and worsening OS (HR = 2.86, 95%CI 1.06–7.70, p = 0.038). The presence of HLA-B27 was associated with improved PFS (HR = 0.35, 95%CI 0.18–0.71, p = 0.004) and trends toward improving OS. None of the HLA-I supertypes were associated with the development or worsening of irAEs. Conclusions: The absence of association between genomic HLA-I/-II homozygosity and clinical outcome among patients with advanced NSCLC treated with pembrolizumab in combination with chemotherapy might reflect a diminished role for HLA molecules among patients with low or no PD-L1. HLA-A01 and HLA-B27 might have a role in predicting clinical outcomes among this cohort of patients. Further studies are needed to explore biomarkers for this group of patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研1完成签到,获得积分10
2秒前
普外科老白完成签到,获得积分10
3秒前
可以2完成签到,获得积分10
6秒前
解解闷发布了新的文献求助10
6秒前
拼搏山槐完成签到 ,获得积分10
6秒前
kekao完成签到,获得积分10
7秒前
8秒前
嘿嘿嘿完成签到,获得积分10
10秒前
摘星012完成签到 ,获得积分10
12秒前
honne完成签到,获得积分10
13秒前
123发布了新的文献求助100
16秒前
17秒前
我是老大应助DVD采纳,获得10
19秒前
诗梦完成签到,获得积分10
19秒前
20秒前
高贵的思天完成签到,获得积分10
20秒前
上好佳完成签到 ,获得积分10
20秒前
打工人一枚完成签到,获得积分10
20秒前
周一一完成签到,获得积分10
21秒前
渔婆完成签到,获得积分10
21秒前
coolplex发布了新的文献求助10
22秒前
寒冷平蓝发布了新的文献求助10
22秒前
DJ完成签到,获得积分10
22秒前
23秒前
24秒前
25秒前
共享精神应助郑书亚采纳,获得10
26秒前
HEIKU应助司空豁采纳,获得10
26秒前
27秒前
金金金金完成签到,获得积分10
28秒前
29秒前
唐同学完成签到 ,获得积分10
30秒前
略略略发布了新的文献求助10
30秒前
30秒前
来了来了完成签到 ,获得积分10
35秒前
36秒前
37秒前
lemon应助334niubi666采纳,获得10
38秒前
39秒前
今后应助123采纳,获得10
39秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Cognitive Paradigms in Knowledge Organisation 2000
Effect of reactor temperature on FCC yield 2000
Near Infrared Spectra of Origin-defined and Real-world Textiles (NIR-SORT): A spectroscopic and materials characterization dataset for known provenance and post-consumer fabrics 610
Introduction to Spectroscopic Ellipsometry of Thin Film Materials Instrumentation, Data Analysis, and Applications 600
Promoting women's entrepreneurship in developing countries: the case of the world's largest women-owned community-based enterprise 500
Shining Light on the Dark Side of Personality 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3308460
求助须知:如何正确求助?哪些是违规求助? 2941800
关于积分的说明 8505877
捐赠科研通 2616792
什么是DOI,文献DOI怎么找? 1429755
科研通“疑难数据库(出版商)”最低求助积分说明 663888
邀请新用户注册赠送积分活动 648999